But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
Hedge fund managers offer up some investment ideas.
This corrective action has me feeling optimistic about some new opportunities.
Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.